Recent Updates
Recently added Catalysts

RO7965032

Phase 2

Geographic Atrophy Secondary to Age-Related Macular Degeneration | Small Molecules | Ophthalmology |Roche Holding AG|Trials Updated: Oct 26, 2026

RO7965032 development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Oct 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment321

FDA Designations

No designations recorded

RO7965032 clinical trials

RO7965032 · 1 trial · 1 indication

Phase 2 1
NCT07851259A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationGeographic Atrophy Secondary to Age-Related Macular Degeneration
RECRUITING321 Analytics
PHASE2RECRUITING
A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Geographic Atrophy Secondary to Age-Related Macular DegenerationUnlock trial analytics

Study Endpoints

Primary Endpoints

Change of GA Lesion Area in the Study Eye
Baseline up to approximately 48 weeks
Incidence and Severity of Ocular Adverse Events (AEs)
Up to approximately 72 Weeks
Incidence and Severity of Non-Ocular AEs
Up to approximately 72 Weeks

Secondary Endpoints

Change of GA Lesion Area in the Study Eye
Baseline up to approximately 72 weeks
Change from Baseline in Best Correct Visual Acuity (BCVA) Score on the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart
Baseline up to approximately 48 weeks
Change from Baseline in BCVA Score on the ETDRS Chart Under Low-luminance Conditions
Baseline up to approximately 48 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
RO7965032 Dose Level 1EXPERIMENTALParticipants will receive RO7965032.
RO7965032 Dose Level 2EXPERIMENTALParticipants will receive RO7965032.
PlaceboPLACEBO_COMPARATORParticipants will receive placebo.

Interventions

NameTypeDescription
RO7965032DRUGRO7965032 will be administered as per the schedule defined in the protocol.
PlaceboDRUGPlacebo will be administered as per the schedule defined in the protocol.
Unlock Study Design Details

Eligibility Criteria

Age Range50 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites5

Inclusion Criteria: Ocular Inclusion Criteria for the Study Eye * BCVA score of \>= 35 letters using the ETDRS VA chart at a starting distance of 4 meters * Lesions may be either extrafoveal or subfoveal Ocular Inclusion Criteria for Both Eyes * Sufficiently clear ocular media, adequate pupillar...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWOct 26, 2026NCT07851259Status: NOT_YET_RECRUITING → RECRUITING
LOWOct 26, 2026NCT07851259Status: NOT_YET_RECRUITING → RECRUITING
LOWOct 26, 2026NCT07851259Status: NOT_YET_RECRUITING → RECRUITING
LOWOct 1, 2026NCT07851259NEW_TRIAL: changed
LOWOct 1, 2026NCT07851259NEW_TRIAL: changed

Frequently asked questions about RO7965032

What is RO7965032 used for in geographic atrophy?

RO7965032 is an investigational small molecule being studied for the treatment of geographic atrophy secondary to age-related macular degeneration, an advanced form of dry AMD that causes progressive loss of central vision. It is in Phase 2 clinical development and has not been approved for any use.

Who is developing RO7965032?

RO7965032 is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is running the compound's clinical program in ophthalmology, with geographic atrophy secondary to age-related macular degeneration as the studied indication.

What phase is RO7965032 in?

RO7965032 is in Phase 2 clinical development. It is investigational and is being evaluated in a single recruiting Phase 2 study in participants with geographic atrophy secondary to age-related macular degeneration. The program has no completed trials to date.

What clinical trial is RO7965032 in?

RO7965032 is being studied in trial NCT07851259, a Phase 2 study assessing its efficacy and safety in participants with geographic atrophy secondary to age-related macular degeneration. The trial is currently recruiting in the United States and is expected to enroll 321 participants aged 50 years and older.

How is the RO7965032 trial designed?

The Phase 2 trial of RO7965032, NCT07851259, is a randomized, double-blind, placebo-controlled study enrolling 321 participants with geographic atrophy secondary to age-related macular degeneration. It accepts participants of all sexes aged 50 years and older and does not enroll healthy volunteers.